1. Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
   Houbao Huang et al, 2020, Frontiers in Oncology CrossRef
2. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance
   Joshua Altschuler et al, 2021, International Journal of Molecular Sciences CrossRef
3. Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions
   Rafaella S. Coelho et al, 2023, BioChem CrossRef
4. Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma
   Chao Shang et al, 2019, Frontiers in Oncology CrossRef
5. Evaluation of Novel Diaza Cage Compounds as MRP Modulators in Cancer Cells
   Henry Döring et al, 2025, Anti-Cancer Agents in Medicinal Chemistry CrossRef
6. Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics
   Joseph Berthier et al, 2019, Life Sciences CrossRef
7. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
   Brandon Bumbaca et al, 2018, Acta Pharmaceutica Sinica B CrossRef
8. Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives
   Ahmed Elfadadny et al, 2021, Environmental Science and Pollution Research CrossRef
9. Novel thermoresponsive star-liked nanomicelles for targeting of anticancer agent
   Aliyeh Ghamkhari et al, 2018, European Polymer Journal CrossRef
10. Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence
    Hiroyoshi Suzuki et al, 2024, International Journal of Urology CrossRef